Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian Thomas

Showing results (81-90 of 111) with videos related to

Pageof 12
Sort By:
Leukemia|August 21, 2024
Optimal prognostic threshold for measurable residual disease positivity by multiparameter flow cytometry in acute myeloid leukemia (AML)Eduardo Rodríguez-Arbolí, Megan Othus, Sylvie D Freeman, et al.
BMJ Open|December 17, 2025
Critical time intervention for people leaving prison at risk of homelessness in England and Wales (PHaCT trial): a pilot feasibility randomised controlled trialAdam Dale Newman Williams, Nina Jacob, Detelina Grozeva, et al.
Leukemia|September 11, 2025
Acute myeloid leukaemia cells express high levels of androgen receptor but do not depend on androgen signaling for survivalFarideh Miraki-Moud, Linda Ariza-McNaughton, Thinzar KoKo, et al.
Blood|June 25, 2026
Combining Quizartinib with intensive chemotherapy in older patients with newly diagnosed AML: results of the UK NCRI AML18 TrialSteven Knapper, Abin Thomas, Robert K Hills, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 31, 2018
Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 MutationsSylvie D Freeman, Robert K Hills, Paul Virgo, et al.
Biorxiv : the Preprint Server for Biology|November 16, 2022
mRNA bivalent booster enhances neutralization against BA.2.75.2 and BQ.1.1Meredith E Davis-Gardner, Lilin Lai, Bushra Wali, et al.
British Journal of Haematology|December 27, 2021
A novel algorithmic approach to generate consensus treatment guidelines in adult acute myeloid leukaemiaThomas Coats, Daniel Bean, Aymeric Basset, et al.
Hemasphere|August 27, 2025
A pooled analysis of 3 large multicenter trials confirms a survival advantage for <i>NPM1</i> <sup>mut</sup> AML in MRD<sup>neg</sup> remission after intensive inductionKonstanze Döhner, Hartmut Döhner, Daniela Späth, et al.
Blood|February 16, 2024
Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remissionJad Othman, Nicola Potter, Adam Ivey, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|October 14, 2024
Prevention and management of infectious and tropical diseases in kidney transplant recipients residing in European outermost and overseas territoriesLaurène Cachera, Erwan Oehler, Karim Abdelmoumen, et al.
Pageof 12

Showing results (81-90 of 111) with videos related to

Sort By:
Pageof 12
Leukemia|August 21, 2024
Optimal prognostic threshold for measurable residual disease positivity by multiparameter flow cytometry in acute myeloid leukemia (AML)Eduardo Rodríguez-Arbolí, Megan Othus, Sylvie D Freeman, et al.
BMJ Open|December 17, 2025
Critical time intervention for people leaving prison at risk of homelessness in England and Wales (PHaCT trial): a pilot feasibility randomised controlled trialAdam Dale Newman Williams, Nina Jacob, Detelina Grozeva, et al.
Leukemia|September 11, 2025
Acute myeloid leukaemia cells express high levels of androgen receptor but do not depend on androgen signaling for survivalFarideh Miraki-Moud, Linda Ariza-McNaughton, Thinzar KoKo, et al.
Blood|June 25, 2026
Combining Quizartinib with intensive chemotherapy in older patients with newly diagnosed AML: results of the UK NCRI AML18 TrialSteven Knapper, Abin Thomas, Robert K Hills, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 31, 2018
Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 MutationsSylvie D Freeman, Robert K Hills, Paul Virgo, et al.
Biorxiv : the Preprint Server for Biology|November 16, 2022
mRNA bivalent booster enhances neutralization against BA.2.75.2 and BQ.1.1Meredith E Davis-Gardner, Lilin Lai, Bushra Wali, et al.
British Journal of Haematology|December 27, 2021
A novel algorithmic approach to generate consensus treatment guidelines in adult acute myeloid leukaemiaThomas Coats, Daniel Bean, Aymeric Basset, et al.
Hemasphere|August 27, 2025
A pooled analysis of 3 large multicenter trials confirms a survival advantage for <i>NPM1</i> <sup>mut</sup> AML in MRD<sup>neg</sup> remission after intensive inductionKonstanze Döhner, Hartmut Döhner, Daniela Späth, et al.
Blood|February 16, 2024
Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remissionJad Othman, Nicola Potter, Adam Ivey, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|October 14, 2024
Prevention and management of infectious and tropical diseases in kidney transplant recipients residing in European outermost and overseas territoriesLaurène Cachera, Erwan Oehler, Karim Abdelmoumen, et al.
Pageof 12